Loading
FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Cervical cancer and 5 more.
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signalling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.99, animal model 0.59, genetic association 0.18, somatic mutation 0.78). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Cervical Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma.
In plain words · FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Cervical cancer and 5 more.
FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Cervical cancer and 5 more.
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor.
No product in this corpus aims at FAS yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA FAS: RNA low tissue specificity; blood lineage group enriched (granulocytes 101 nTPM, T-cells 91 nTPM); no normal tissue stained high; highest cancer staining ovarian cancer (1 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia, Cervical cancer, Skin cancer (all types)); Open Targets associates it with 3 specific cancer types at or above 0.5 (autoimmune lymphoproliferative syndrome type 1, autoimmune lymphoproliferative syndrome, lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P25445; CIViC gene FAS; IntOGen FAS; Human Protein Atlas FAS tissue; Open Targets ENSG00000026103 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Itoh et al, Cell, 1991, "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis". Source.
Sources: HGNC HGNC:11920 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P25445 (protein name, function text, keywords and locations (REST API)); CIViC gene FAS (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000026103 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: melanoma 0.52, acute lymphoblastic leukaemia 0.50, diffuse large B-cell lymphoma 0.59, non-Hodgkin lymphoma 0.71, skin cancer 0.52, leukaemia 0.63 (GraphQL API, CC0)); IntOGen FAS (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signalling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). Location: Cell membrane; Membrane raft; Secreted (UniProt). Locus 10q23.31 (HGNC).
RNA: low tissue specificity, detected in many normal tissues. Blood: group enriched (granulocytes 101 nTPM, T-cells 91 nTPM).
No normal tissue stained high.
Medium only: breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
HPA FAS tissue · HPA FAS pathology · HPA protein class: CD markers
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FAS" OR ABSTRACT:"FAS" OR TITLE:"Fas cell surface death receptor" OR ABSTRACT:"Fas cell surface death receptor" OR TITLE:"Tumor necrosis factor receptor superfamily member 6" OR ABSTRACT:"Tumor necrosis factor receptor superfamily member 6" OR TITLE:"CD95" OR ABSTRACT:"CD95" OR TITLE:"APO-1" OR ABSTRACT:"APO-1" OR TITLE:"FAS1" OR ABSTRACT:"FAS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAS, not a curated reading list.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Leukaemia (all types), Skin cancer (all types), CIViC, IntOGen.
Shares Marginal zone lymphoma, Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.